Compositions and methods for immunooncology
US-2024417722-A1 · Dec 19, 2024 · US
Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
US11912753B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11912753-B2 |
| Application number | US-202117353414-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 21, 2021 |
| Priority date | Sep 22, 2011 |
| Publication date | Feb 27, 2024 |
| Grant date | Feb 27, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.
First claim
Opening claim text (preview).
What is claimed: 1. An isolated biotin binding immune receptor (BBIR) comprising an extracellular binding domain, a transmembrane domain, a T cell receptor signaling domain, and an intracellular domain of a costimulatory molecule, wherein the extracellular binding domain comprises avidin in monomeric or dimeric form, wherein the BBIR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8-10. 2. The isolated BBIR of claim 1 , wherein the extracellular binding domain binds to a biotinylated antibody or antibody fragment. 3. The isolated BBIR of claim 2 , wherein the biotinylated antibody or antibody fragment binds to an antigen selected from the group consisting of a tumor antigen, a self-antigen, a viral antigen, and any combination thereof. 4. A cell comprising the BBIR of claim 1 . 5. The cell of claim 4 , wherein the extracellular binding domain of the BBIR binds to a biotinylated antibody or antibody fragment. 6. The cell of claim 5 , wherein the biotinylated antibody or antibody fragment binds to an antigen selected from the group consisting of a tumor antigen, a self-antigen, a viral antigen, and any combination thereof. 7. The cell of claim 4 , wherein the cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell. 8. An isolated biotin binding immune receptor (BBIR) comprising an extracellular binding domain, a transmembrane domain, a T cell receptor signaling domain, and an intracellular domain of a costimulatory molecule, wherein the extracellular binding domain comprises avidin in monomeric or dimeric form, wherein the BBIR is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NOs: 11, 15, and 16. 9. The isolated BBIR of claim 8 , wherein the extracellular binding domain binds to a biotinylated antibody or antibody fragment. 10. The isolated BBIR of claim 8 , wherein the biotinylated antibody or antibody fragment binds to an antigen selected from the group consisting of a tumor antigen, a self-antigen, a viral antigen, and any combination thereof. 11. A cell comprising the isolated BBIR of claim 8 . 12. The cell of claim 11 , wherein the extracellular binding domain of the BBIR binds to a biotinylated antibody or antibody fragment. 13. The cell of claim 12 , wherein the biotinylated antibody or antibody fragment binds to an antigen selected from the group consisting of a tumor antigen, a self-antigen, a viral antigen, and any combination thereof. 14. The cell of claim 11 , wherein the cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), and a regulatory T cell.
Assignees
Inventors
Classifications
- C07K14/7051Primary
T-cell receptor (TcR)-CD3 complex · CPC title
the antibody targeting a determinant of a tumour cell · CPC title
from birds · CPC title
CD8 · CPC title
CD28, CD152 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11912753B2 cover?
- The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.
- Who is the assignee on this patent?
- Univ Pennsylvania
- What technology area does this patent fall under?
- Primary CPC classification C07K14/7051. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).